Guy Macdonald to Join the Board of Directors of Spring Bank Pharmaceuticals
(Milford, Ma.) Spring Bank Pharmaceuticals announced today that Guy Macdonald, CEO and President of Tetraphase Pharmaceuticals will join Spring Bank’s Board of Directors.
"I would like to personally welcome Guy to our Board," said Doug Jensen,. President and Chief Executive Officer of Spring Bank. "We are very fortunate to have someone who will bring energy, insight, and a wealth of pharmaceutical industry experience to our Board as we continue to develop our drug discovery platform . Guy is a 25-year veteran of the global pharmaceutical and biotechnology sector which included twenty-two years at Merck & Co., where he served as a senior leader in the areas of virology and anti-infectives and was
involved in several landmark launches at a global level.“
About Spring Bank Pharmaceuticals, Inc: Spring Bank Pharmaceuticals, Inc. is a novel drug discovery company with a breakthrough drug for Hepatitis C and Hepatitis B for which we plan to begin Phase 1 trials in early 2011. For more on Spring Bank, please visit http://www.springbankpharm.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Various statements in this release are "forward-looking statements" under the securities laws. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," and "could," and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the company's forward-looking statements include, among others: the extent and effectiveness of the development of SB9000 receives; Spring Bank’s delays in the completion of pre-clinical and clinical trials; a failure of Spring Bank’s products to be demonstrably safe and effective; Spring Bank’s failure to obtain regulatory approval for its products or to comply with ongoing regulatory requirements for its products; a lack of acceptance of Spring Bank’s products in the marketplace, or a failure to become or remain profitable; Spring Bank's expectations regarding trends with respect to its costs and expenses; Spring Bank's inability to obtain the capital necessary to fund its research and development activities; Spring Bank's failure to identify or obtain rights to new products; Spring Bank's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; a loss of any of Spring Bank's key scientists or management personnel; losses incurred from product liability claims made against Spring Bank; a loss of rights to develop and commercialize Spring Bank's products under its potential license and sublicense agreements. There can be no assurance that the actual results or developments anticipated by Spring Bank will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Spring Bak. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.
All written and verbal forward-looking statements attributable to Spring Bank or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Spring Bank cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Spring Bank Pharmaceuticals, Inc.
About Hepatitis
Over 350 million people are chronically infected with HBV virus worldwide. The HBV virus is a DNA virus which incorporates into the hepatocyte DNA. Read More >>
Approximately 170 million people worldwide and 4 million in the United States are infected with HCV. HCV infection is one of the most significant public health threats facing Americans.
Read More >>
